三种肾动脉桥接覆膜支架在胸腹主动脉病变分支腔内修复中的三年性能数据
该单中心回顾性分析纳入2010至2019年接受分支腔内动脉瘤修复、至少植入一枚Advanta、Advanta+VSX或VBX作为肾动脉桥接支架的255例患者共431枚肾动脉桥接支架。中位随访19.3个月,三年时Advanta组、Advanta+VSX组和VBX组的估计一期通畅率分别为82.7±4.6%、96.8±1.8%和89.0±3.2%。作者认为球囊扩张覆膜支架联合远端自膨式覆膜支架在通畅率方面似乎优于单用球囊扩张覆膜支架。
要点
- 255例患者共植入431枚肾动脉桥接支架,中位随访19.3个月。
- 三年一期通畅率:Advanta组82.7±4.6%,Advanta+VSX组96.8±1.8%,VBX组89.0±3.2%。
- 作者认为球囊扩张覆膜支架联合远端自膨式覆膜支架在通畅率方面似乎优于单用球囊扩张覆膜支架。
核心结论
- 球囊扩张覆膜支架联合远端自膨式覆膜支架在通畅率方面似乎优于单用球囊扩张覆膜支架。
研究设计与样本
- 单中心前瞻性收集数据的回顾性分析,纳入接受分支腔内动脉瘤修复且至少一枚Advanta、Advanta+VSX或VBX作为肾动脉桥接支架的患者。
- 共纳入255例患者、431枚肾动脉桥接支架,治疗时间为2010年至2019年。
- 植入支架数:Advanta 125枚,Advanta+VSX 146枚,VBX 160枚。
- Advanta主要用于2010至2014年,Advanta+VSX用于2015至2017年,VBX用于2018至2019年。
- 数据分析采用Kaplan-Meier估计和多变量Cox回归。
主要发现
- 中位随访19.3个月。
- 三年估计一期通畅率:Advanta组82.7±4.6%,Advanta+VSX组96.8±1.8%,VBX组89.0±3.2%。
- 三年估计免于靶血管不稳定率:Advanta组82.4±4.7%,Advanta+VSX组94.1±2.4%,VBX组85.4±3.5%。
- 三年估计免于再干预率:Advanta组86.3±3.4%,Advanta+VSX组95.1±2.0%,VBX组91.6±2.4%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Previous studies have shown that branched endovascular aneurysm repair (B-EVAR) carries a significant risk of adverse renal events. The purpose of this study was to evaluate the performance of the balloon expandable covered stentgraft (BECS) Advanta/iCast V12, the Viabahn balloon expandable stent (VBX), and the BECS Advanta stent combined with a distally deployed self expanding covered stentgraft (SECS) Viabahn (VSX) as bridging stent grafts (BSGs) in renal arteries. METHODS: A retrospective analysis of prospectively collected data was conducted at a single centre. Patients undergoing B-EVAR who had at least one Advanta, Advanta + VSX, or VBX as renal artery BSGs were included. Endpoints were patency, endoleaks, target vessel instability (TVI), re-interventions, as well as clinical outcomes including kidney function, new dialysis needs, and death. Data were analysed using Kaplan-Meier estimates and multivariable Cox regression. RESULTS: The study included 255 patients with 431 renal artery BSGs treated by complex aortic repair between 2010 and 2019. Advanta was used predominantly in 2010 - 2014, Advanta + VSX in 2015 - 2017, and VBX in 2018 - 2019. Overall, 125 Advanta, 146 Advanta + VSX, and 160 VBX stents were implanted. The median follow up was 19.3 months. At three years, estimated primary patencies were 82.7 ± 4.6% for renal arteries treated with Advanta, 96.8 ± 1.8% for Advanta + VSX, and 89.0 ± 3.2% for VBX. Estimated freedom from TVI at three years was 82.4 ± 4.7% for renal arteries treated with Advanta, 94.1 ± 2.4% for Advanta + VSX, and 85.4 ± 3.5% for VBX. Freedom from re-intervention estimations at three years were 86.3 ± 3.4% in the Advanta cohort, 95.1 ± 2.0% in the Advanta + VSX cohort, and 91.6 ± 2.4% in the VBX cohort. CONCLUSION: The combination of BECS and SECS seems to be superior in terms of primary patency compared with BECS alone.
引用
- Kolet R, Usai MV, Shehada Y, et al. Three Year Data on the Performance of Three Renal Artery Bridging Stent Grafts in Branched Endovascular Repair of Thoraco-Abdominal Pathologies. Eur J Vasc Endovasc Surg. 2025. PMID: 40015551. doi:10.1016/j.ejvs.2025.02.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。